SGLT2 Inhibition Changing What Fuels the Heart

被引：15

作者：

Lehrke, Michael ^{[1
]}

机构：

[1] Univ Hosp RWTH Aachen, Dept Internal Med 1, Aachen, Germany

来源：

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2019年 / 73卷 / 15期

关键词：

animal models; cardiac remodeling; diabetes; heart failure; myocardial metabolism; SGLT2; inhibition; TYPE-2; DIABETES-MELLITUS; EMPAGLIFLOZIN; OUTCOMES;

D O I：

10.1016/j.jacc.2019.02.023

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1945 / 1947

页数：3

共 17 条

[11] Return to the fetal gene program A suggested metabolic link to gene expression in the heart [J].

Taegtmeyer, Heinrich ;

Sen, Shiraj ;

Vela, Deborah .

ANALYSIS OF CARDIAC DEVELOPMENT: FROM EMBRYO TO OLD AGE, 2010, 1188 :191-198

[12] Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease [J].

Wanner, Christoph ;

Lachin, John M. ;

Inzucchi, Silvio E. ;

Fitchett, David ;

Mattheus, Michaela ;

George, Jyothis ;

Woerle, Hans J. ;

Broedl, Uli C. ;

von Eynatten, Maximilian ;

Zinman, Bernard ;

Aizenberg, D. ;

Ulla, M. ;

Waitman, J. ;

De Loredo, L. ;

Farias, J. ;

Fideleff, H. ;

Lagrutta, M. ;

Maldonado, N. ;

Colombo, H. ;

Ferre Pacora, F. ;

Wasserman, A. ;

Maffei, L. ;

Lehman, R. ;

Selvanayagam, J. ;

d'Emden, M. ;

Fasching, P. ;

Paulweber, B. ;

Toplak, H. ;

Luger, A. ;

Drexel, H. ;

Prager, R. ;

Schnack, C. ;

Schernthaner, G. ;

Fliesser-Goerzer, E. ;

Kaser, S. ;

Scheen, A. ;

Van Gaal, L. ;

Hollanders, G. ;

Kockaerts, Y. ;

Capiau, L. ;

Chachati, A. ;

Persu, A. ;

Hermans, M. ;

Vantroyen, D. ;

Vercammen, C. ;

Van de Borne, P. ;

Mathieu, C. ;

Benhalima, K. ;

Lienart, F. ;

Mortelmans, J. .

CIRCULATION, 2018, 137 (02) :119-129

[13]

Wende Adam R, 2017, JACC Basic Transl Sci, V2, P297, DOI 10.1016/j.jacbts.2016.11.009

[14]

Wiviott SD, 2019, NEW ENGL J MED, V380, P347, DOI [10.1056/NEJMoa1812389, 10.1056/NEJMc1902837]

[15] Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. [J].

Zannad, Faiez ;

McMurray, John J. V. ;

Krum, Henry ;

van Veldhuisen, Dirk J. ;

Swedberg, Karl ;

Shi, Harry ;

Vincent, John ;

Pocock, Stuart J. ;

Pitt, Bertram .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (01) :11-21

[16] SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials [J].

Zelniker, Thomas A. ;

Wiviott, Stephen D. ;

Raz, Itamar ;

Im, Kyungah ;

Goodrich, Erica L. ;

Bonaca, Marc P. ;

Mosenzon, Ofri ;

Kato, Eri T. ;

Cahn, Avivit ;

Furtado, Remo H. M. ;

Bhatt, Deepak L. ;

Leiter, Lawrence A. ;

McGuire, Darren K. ;

Wilding, John P. H. ;

Sabatine, Marc S. .

LANCET, 2019, 393 (10166) :31-39

[17] Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes [J].